SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada).